UPDATE: Oppenheimer Starts Cincor Pharma Inc (CINC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to UPDATE: Oppenheimer Starts Cincor Pharma Inc (CINC) at Outperform
February 1, 2022 6:33 AM EST
Evercore ISI analyst Michael DiFiore initiates coverage on Cincor Pharma Inc (NASDAQ: CINC) with a Outperform rating.
The analyst comments "Cincor is a cardio-renal-focused company whose only drug (CIN-107) a highly selective/potent inhibitor of aldosterone synthase, the enzyme that catalyzes the formation of aldosterone.... More
February 1, 2022 3:52 AM EST
(Updated - February 1, 2022 4:52 AM EST)
Jefferies analyst Dennis Ding initiates coverage on Cincor Pharma Inc (NASDAQ: CINC) with a Buy rating and a price target of $30.00.
The analyst comments "CINC has a differentiated pill, CIN-107, for difficult to... More
February 1, 2022 3:13 AM EST
(Updated - February 1, 2022 5:53 AM EST)
Morgan Stanley analyst Jeffrey Hung initiates coverage on Cincor Pharma Inc (NASDAQ: CINC) with a Overweight rating and a price target of $27.00.
The analyst comments "CIN-107 initial data demonstrate a targeted approach with a favorable... More
